Member news

MORF-Bio has secured an Innovate UK Investor Partnerships Award, unlocking a new investment round led by Deeptech Seed Fund and matched by Helix Research and Enterprise.

Last month, the multi-award-winning Advanced Therapies Apprenticeship Community (ATAC) welcomed its 400th member. 

Aravax today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy.

NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026.

Find out more about a free, independent review of R&D tax claims for BIA members.

Touchlight announced the first UK patient was dosed with a bespoke cancer vaccine manufactured using its proprietary dbDNA technology.

Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.

TauRx gathered representatives from leading patient advocacy groups including Alzheimer Europe, Alzheimer Scotland and Alzheimer's Disease International to Scotland House in London.

Moa Technology announces a £22.2 million Series C financing round

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

ELRIG has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB).

Lonza and Engitix announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs).

tranScrip recently hosted its Ask the Experts Live Q&A: From Preclinical to First-in-Human. If you couldn't join us live, the full recording is now available to watch on demand at your convenience.

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

Theolytics has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus.

Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.

The British Business Bank has invested in Draig Therapeutics as part of its $65 million Series B financing round.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Milner Institute convenes science, industry, investors and charity funders for Pitch Day and Symposium

Some of the UK's most promising student food innovators gathered at Colworth Science Park this month for the 2026 Ecotrophelia UK final, where seven university teams presented eco-innovative food concepts to a panel of industry judges.